Safety and treatment adherence of commonly prescribed typical and atypical antipsychotics in schizophrenic patients in a tertiary care hospital
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20164097Keywords:
Efficacy, Haloperidol, Olanzapine, Risperidone, Schizophrenia, Treatment adherenceAbstract
Background: Schizophrenia is a chronic mental disorder characterized by delusions, hallucinations, incoherence and physical agitation. Presently available drugs in the treatment of Schizophrenia are typical and atypical antipsychotics which act on various neurotransmitters like Dopamine, Serotonin and Acetylcholine. Though both classes of drugs are effective in treatment, they differ in tolerability and treatment adherence. Hence present study has been taken to compare safety and treatment adherence of typical and atypical antipsychotics.
Methods: It was a comparative study conducted on 90 patients of Schizophrenia for one year. The study subjects were randomly assigned into 3 groups of 30 patients each. Group 1 were treated with Risperidone, group 2 with Olanzapineand and group 3 with Haloperidol. Safety was measured by Abnormal involuntary movement scale, Barnes akathisia scale, Simpson angus scale and pattern of adverse effects in each group. Treatment adherence was measured by number of dropout subjects and pill count.
Results: Barnes akathisia scale and Simpson angus scale showed one point improvement in Risperidone and Olanzapine group where as one point worsening in haloperidol group. Abnormal involuntary movement scale showed low scores in haloperidol group. Extra Pyramidal symptoms were more common adverse effect in Haloperidol group where as weight gain in Olanzapine and Risperidone group. Pill count was more in Olanzapine group than Risperidone and Haloperidol group.
Conclusions: The adverse effect like extrapyramidal symptoms is more common among haloperidol. Weight gain was common in olanzapine treated patients than Risperidone treated patients but treatment adherence was better in Olanzapine treated patients.
References
Gelder MG, Lopez-Ibor. JJ, Andreasen N, editors. New Oxford Textbook of Psychiatry. Volume 1, 2ed. New York: Oxford university press; 2000:567-636.
Gosh A, Chakraborty K, Mattoo SK. Newer molecule in the treatment of schizophrenia: A clinical update. Indian journal of Pharmacology. 2011;43(2):105-12.
Sharma HL, Sharma KK,editors. Principles of Pharmaclogy. 2nd edition. Paras publication; 2011:451-460.
Lieberman AJ, Tollefson G, Tolen M, Dr. P.H, Green AI, Gur RE et al, Comparative efficacy and safety of atypical antipsychotic drugs in first-episode psychosis: A randomized, double blind trial of olanzapine versus haloperidol. American Journal of Psychiatry. 2003;160:1396-404.
Bruton LL, Lazo JS, Parker KL, editors. Goodman and Gillman’s The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw hill; 2001:485-507.
Kannabiran M, Singh V. Metabolic syndrome and atypical antipsychotic: A selective literature review. German journal of psychiatry. 2008;11:111-22.
Lieberman AJ, Tollefson G, Tolen M, Dr. P.H, Green AI, Gur RE et al, Comparative efficacy and safety of atypical antipsychotic drugs in first-episode psychosis: A randomized, double blind trial of olanzapine versus haloperidol. American Journal of Psychiatry. 2003;160:1396-404.
Tollefson D G et al. Olanzapine versus Haloperidol in the Treatment of Schizophrenia and Schizoaffective and Schizophreniform Disorders: Results of an International Collaborative Trial. American Journal of Psychiatry. 1997;154:457-46.
Katzung BG, Masters SB, Trevors AJ. Basic and Clinical Pharmacology. 11th ed. New York: Tata McGraw Hill Education Private Limited; 2009: 665-669.
Kapur S and Remington G. Atypical Antipsychotics: New Directions and New Challenges in the Treatment of Schizophrenia. Annual Review of Medicine. 2001;52:503-17.
Allison DB, Mentor JL, Moonseong H, Chandler LP, Cappelleri JC, Infante MC and Weiden PJ, Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis American Journal of Psychiatry. 1999;156:1686-96.
Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight change in patients with Schizophrenia treated with olanzapine, Haloperidol, or risperidone. Journal of Clinical Psychiatry. 2001;62(4):231-8.
Wetterling T. Body weight gain with atypical antipsychotics. A comparative review. Drug Safety. 2001;24(1):59-73.
Haddad P. Weight change with atypical antipsychotics in the treatment of Schizophrenia. Journal of Psychopharmacology. 2005;19:16-27.
Lee E, Leung CM, Wong E. Atypical antipsychotics and weignt gain in Chinese patients: A Comparision of olanzapine and risperidone. Journal of Clinical Psychiatry. 2004:65-66.
Conley RR and Mahmoud R. A Randomized Double-Blind Study of Risperidone and Olanzapine in the Treatment of Schizophrenia or Schizoaffective Disorder. American Journal of Psychiatry. 2001;158:765-74.
